Drug Pipeline Reviews

Drug Development Pipeline Reviews by Therapy Area

Douglas Insights tracks 11,980 drug candidates in clinical development across 156 therapy areas, 2,160 of them in Phase III, counted from 79,489 interventional trials and refreshed every 90 days.

Request a custom review Browse therapy areas

11,980 candidates tracked79,489 registered trialsRefreshed every 90 daysExcel tracker with every review

Therapy areas

Which therapy areas does Douglas Insights cover?

Each therapy area has a free public page with the pipeline by phase, the leading sponsors and the next readouts, built from the same frozen dataset as the paid review.

Therapy area

Non-Small Cell Lung Cancer drug pipeline

903 non-small cell lung cancer candidates in clinical development from 352 sponsors, 157 readouts due in the next 12 months.

Phase III: 181
Phase II: 213
Phase I: 509
3,414 trials

See the non-small cell lung cancer pipeline →Data as of 3 Oct 2026

Therapy area

Breast Cancer drug pipeline

645 breast cancer candidates in clinical development from 321 sponsors, 89 readouts due in the next 12 months.

Phase III: 111
Phase II: 143
Phase I: 391
4,202 trials

See the breast cancer pipeline →Data as of 3 Oct 2026

Therapy area

Colorectal Cancer drug pipeline

525 colorectal cancer candidates in clinical development from 264 sponsors, 56 readouts due in the next 12 months.

Phase III: 27
Phase II: 113
Phase I: 385
2,088 trials

See the colorectal cancer pipeline →Data as of 3 Oct 2026

Therapy area

Head and Neck Squamous Cell Carcinoma drug pipeline

520 head and neck squamous cell carcinoma candidates in clinical development from 263 sponsors, 69 readouts due in the next 12 months.

Phase III: 47
Phase II: 130
Phase I: 343
2,748 trials

See the head and neck squamous cell carcinoma pipeline →Data as of 3 Oct 2026

Therapy area

Melanoma drug pipeline

401 melanoma candidates in clinical development from 190 sponsors, 35 readouts due in the next 12 months.

Phase III: 42
Phase II: 93
Phase I: 266
1,463 trials

See the melanoma pipeline →Data as of 3 Oct 2026

Therapy area

Gastric Cancer drug pipeline

393 gastric cancer candidates in clinical development from 190 sponsors, 73 readouts due in the next 12 months.

Phase III: 49
Phase II: 98
Phase I: 246
1,370 trials

See the gastric cancer pipeline →Data as of 3 Oct 2026

Cardiovascular 8

Therapy area	Candidates	Phase III	Sponsors	Trials
Atherosclerosis	34	16	25	433
Atrial Fibrillation	14	4	12	408
Heart Failure	94	16	56	948
Hypercholesterolemia	67	24	35	424
Hypertension	195	73	102	1,591
Hypertrophic Cardiomyopathy	8	2	8	79
Myocardial Infarction	24	11	23	440
Peripheral Artery Disease	15	5	13	189

Dermatology 6

Therapy area	Candidates	Phase III	Sponsors	Trials
Acne	13	4	12	252
Alopecia	47	15	37	258
Atopic Dermatitis	133	25	88	663
Glabellar Lines	12	8	10	80
Hidradenitis Suppurativa	35	7	25	132
Psoriasis	87	29	68	785

Gastroenterology & Hepatology 3

Therapy area	Candidates	Phase III	Sponsors	Trials
Crohn's Disease	39	4	32	398
MASH	82	13	56	507
Ulcerative Colitis	75	12	54	492

Hematology 5

Therapy area	Candidates	Phase III	Sponsors	Trials
Hemophilia	33	19	22	247
Immune Thrombocytopenia	39	11	38	243
Paroxysmal Nocturnal Hemoglobinuria	28	14	23	111
Polycythemia Vera	24	7	21	136
Sickle Cell Disease	28	5	24	324

Immunology & Inflammation 2

Therapy area	Candidates	Phase III	Sponsors	Trials
Chronic Urticaria	28	8	27	121
Rheumatoid Arthritis	99	12	71	545

Infectious Disease 10

Therapy area	Candidates	Phase III	Sponsors	Trials
Chickenpox	13	10	10	159
Dengue	8	2	7	103
HIV	77	13	26	1,812
Hepatitis B	60	10	36	325
Herpes Zoster	13	1	13	168
Malaria	24	1	10	328
Meningococcal Disease	10	2	4	69
Pneumococcal Disease	20	7	12	141
RSV	48	7	22	156
Sepsis	21	5	18	541

Metabolic & Endocrine 2

Therapy area	Candidates	Phase III	Sponsors	Trials
Obesity	253	44	129	1,827
Type 2 Diabetes	220	73	101	1,738

Musculoskeletal 3

Therapy area	Candidates	Phase III	Sponsors	Trials
Chronic Low Back Pain	24	11	14	204
Osteoarthritis	84	26	60	832
Osteoporosis	11	3	7	232

Nephrology & Urology 1

Therapy area	Candidates	Phase III	Sponsors	Trials
Chronic Kidney Disease	114	32	68	834

Neurology 14

Therapy area	Candidates	Phase III	Sponsors	Trials
ALS	57	5	51	273
Acute Pain	15	7	15	392
Alzheimer's Disease	139	17	99	754
Chronic Inflammatory Demyelinating Polyneuropathy	16	9	13	53
Epilepsy	43	16	35	518
Huntington's Disease	15	3	13	72
Insomnia	10	6	10	266
Ischemic Stroke	59	12	51	691
Migraine	14	6	12	403
Multiple Sclerosis	55	12	42	526
Multiple System Atrophy	17	3	16	70
Myasthenia Gravis	36	14	29	151
Narcolepsy	11	5	9	55
Postoperative Pain	19	8	18	1,748

Oncology 43

Therapy area	Candidates	Phase III	Sponsors	Trials
Acute Lymphoblastic Leukemia	118	11	75	1,106
Acute Myeloid Leukemia	213	22	143	1,695
Anal Cancer	18	4	15	100
Astrocytoma	152	5	105	844
Basal Cell Carcinoma	20	1	15	108
Bladder Cancer	263	40	146	1,091
Breast Cancer	645	111	321	4,202
Cervical Cancer	188	17	113	666
Cholangiocarcinoma	178	25	105	687
Chronic Lymphocytic Leukemia	92	11	59	722
Chronic Myeloid Leukemia	13	3	13	322
Chronic Myelomonocytic Leukemia	31	2	23	211
Colorectal Cancer	525	27	264	2,088
Cutaneous T-Cell Lymphoma	18	1	18	164
Diffuse Large B-Cell Lymphoma	145	23	91	883
Endometrial Cancer	236	21	126	570
Esophageal Cancer	216	26	113	878
Ewing Sarcoma	15	0	15	149
Follicular Lymphoma	122	15	76	644
Gastric Cancer	393	49	190	1,370
Gastrointestinal Stromal Tumor	16	4	14	112
Glioblastoma	153	5	110	866
Head and Neck Squamous Cell Carcinoma	520	47	263	2,748
Hepatocellular Carcinoma	224	26	128	1,327
Hodgkin Lymphoma	20	3	16	237
Mantle Cell Lymphoma	62	12	44	437
Marginal Zone Lymphoma	40	6	33	284
Melanoma	401	42	190	1,463
Merkel Cell Carcinoma	31	5	24	113
Mesothelioma	64	4	49	262
Multiple Myeloma	215	42	102	1,592
Myelodysplastic Syndromes	141	11	89	839
Myelofibrosis	51	11	31	261
Nasopharyngeal Carcinoma	39	12	27	378
Neuroblastoma	18	1	15	281
Neuroendocrine Tumors	50	13	38	467
Non-Muscle Invasive Bladder Cancer	45	18	32	195
Non-Small Cell Lung Cancer	903	181	352	3,414
Osteosarcoma	43	2	35	298
Peripheral T-Cell Lymphoma	71	13	49	457
Rectal Cancer	70	11	44	695
Renal Cell Carcinoma	245	21	128	855
Sarcoma	223	16	141	1,176

Ophthalmology 7

Therapy area	Candidates	Phase III	Sponsors	Trials
Age-Related Macular Degeneration	143	31	99	521
Diabetic Macular Edema	39	9	35	217
Diabetic Retinopathy	19	6	19	136
Dry Eye Disease	49	8	39	498
Glaucoma	29	10	23	233
Retinal Vein Occlusion	9	5	8	74
Retinitis Pigmentosa	26	5	25	99

Other 31

Therapy area	Candidates	Phase III	Sponsors	Trials
ANCA-Associated Vasculitis	21	3	18	132
Actinic Keratosis	10	4	10	139
Acute Kidney Injury	15	0	14	257
Ankylosing Spondylitis	19	11	17	120
Autosomal Dominant Polycystic Kidney Disease	10	0	10	58
Benign Prostatic Hyperplasia	14	7	9	104
Bipolar Disorder	13	4	12	202
COVID	122	26	79	2,600
Coronary Artery Disease	54	13	46	984
Diabetic Foot Ulcer	18	5	18	145
Diabetic Kidney Disease	16	1	15	157
Eosinophilic Esophagitis	10	3	9	61
Erectile Dysfunction	10	3	9	121
Gastroesophageal Reflux Disease	13	6	11	142
Gout	20	5	18	134
Graft-versus-Host Disease	44	9	34	527
Growth Hormone Deficiency	8	4	5	60
HPV Infection	30	9	22	199
Hypertriglyceridemia	23	6	21	104
Hyperuricemia	13	3	12	76
IgA Nephropathy	44	14	41	150
Influenza	128	21	39	635
Juvenile Idiopathic Arthritis	24	18	16	79
Liver Cirrhosis	57	14	40	544
Myositis	52	5	41	195
Overactive Bladder	6	1	6	154
Peanut Allergy	16	2	16	70
Post-Traumatic Stress Disorder	8	4	8	291
Primary Biliary Cholangitis	13	4	11	80
Primary Immunodeficiency	24	16	21	161
Sjogren's Syndrome	27	5	24	117

Psychiatry 6

Therapy area	Candidates	Phase III	Sponsors	Trials
Agitation	14	5	12	200
Autism Spectrum Disorder	19	7	16	233
Generalized Anxiety Disorder	13	7	12	62
Major Depressive Disorder	65	15	51	705
Opioid Use Disorder	14	2	12	300
Schizophrenia	65	15	44	611

Rare & Genetic 5

Therapy area	Candidates	Phase III	Sponsors	Trials
Alpha-1 Antitrypsin Deficiency	10	2	10	56
Amyloidosis	23	11	18	178
Cystic Fibrosis	43	3	28	252
Duchenne Muscular Dystrophy	32	11	28	151
Hereditary Angioedema	9	7	9	60

Respiratory 9

Therapy area	Candidates	Phase III	Sponsors	Trials
Acute Respiratory Distress Syndrome	28	5	25	329
Allergic Rhinitis	44	21	30	295
Asthma	111	32	58	793
Bronchiolitis Obliterans Syndrome	14	3	12	179
COPD	73	19	46	410
Idiopathic Pulmonary Fibrosis	52	9	46	216
Interstitial Lung Disease	86	15	72	525
Obstructive Sleep Apnea	18	13	14	172
Pulmonary Arterial Hypertension	26	12	23	225

Women's Health 1

Therapy area	Candidates	Phase III	Sponsors	Trials
Infertility	20	12	14	457

The paid review

What does a Douglas Insights pipeline review contain?

Each review is a 40–50 page report with an Excel tracker of every candidate, a 12–24 month catalyst calendar, a mechanism map with white space, and ranked calls on the candidates most likely to win.

11 chapters40–50 pages25 asset profilesExcel tracker of every candidate

01Executive summary and our call2–3 pp

The pipeline on one page and the desk's verdict on where treatment is heading.

Pipeline size and phase mix
The three calls that matter
What changed since the last edition

02Disease and unmet need3 pp

Who is treated today, what current therapy leaves unmet, and how regulators judge new medicines.

Patient population and diagnosis
Treatment guidelines and gaps
Regulatory endpoints

03Approved therapies3 pp

The marketed medicines every candidate will be measured against.

Marketed medicines and their sponsors
Post-approval trials
The bar a new entrant must clear

04Pipeline at a glance4 pp

Every candidate counted by phase, drug type, sponsor and country.

Assets by phase and drug type
Sponsors by size of pipeline
Trial footprint: US, Europe, China, Japan

05Mechanism landscape and white space5 pp

Which mechanisms are crowded and which no sponsor has entered.

Mechanism classes and crowding
Classes with no candidate yet
Differentiation by route and dosing

06Key asset profiles12–15 pp

The leading 25 candidates, one profile each, every claim linked to a source document.

Design and endpoints of the pivotal trials
Data to date, with sources
Next readout and the risk to it

07Catalyst calendar3 pp

Readouts, filings and regulatory decisions 24 months ahead.

Readouts by quarter
Filings and regulatory decisions
Date confidence for each event

08Deals and partnering3 pp

Who is licensing, buying and partnering in the area, and on what terms.

Licensing and M&A in the area
Deal terms where disclosed
Sponsors open to partnering

09Sponsor landscape3 pp

Large pharma against biotech, and how concentrated the pipeline is.

Pipeline share by sponsor
Sponsor-by-phase matrix
New entrants since the last edition

10Our call: winners, risks, opportunities3–4 pp

The candidates most likely to win, ranked, with the reasoning and evidence.

Ranked candidates
Risks that could change the order
Openings for new entrants and investors

11Methodology and source log2 pp

How the count is built and every document behind it.

How candidates are counted and merged
Every source document listed
The ten quality checks

Ways to buy

Option	What you get	Delivery	Price
Pipeline Snapshot	This therapy area as published: PDF report + Excel tracker	Ready now	USD 3,000	Enquire
Pipeline Review	Your indication, geography and phase cut-off; ranked calls and an analyst call	2–3 weeks	From USD 4,000	Enquire
Company Assessment	One sponsor's full pipeline against its peers	2 weeks	From USD 5,000	Enquire

Email me the sample and chapter list Ask for a quote

Method

How are the pipelines counted?

Every count starts from registered interventional trials on ClinicalTrials.gov. The same molecule under its code, generic and brand names is merged into one candidate, and each candidate is placed at the highest phase of its running or recent trials. Placebo, comparator and standard-of-care arms are never counted, and every merge is reviewed by the research desk.

Each edition is one frozen dataset that passes ten checks before release and is approved by the owner. See the research methodology.

Common questions

Drug pipeline reviews: frequently asked questions

How many drug candidates does Douglas Insights track?

11,980 candidates in clinical development across 156 therapy areas, 2,160 of them in Phase III, counted from 79,489 registered trials.

How often are the pipeline reviews updated?

90 days is the refresh cycle: every therapy area is re-harvested from the trial registry, re-checked and re-approved each quarter.

Can Douglas Insights build a review for my indication?

40–50 pages is the standard custom review: your indication, geography and phase cut-off, with ranked calls and an analyst call, delivered with the Excel tracker.

Need a pipeline we have not published?

Tell us the indication. Within one business day the Research Desk will scope a review: the trials in range, the candidates, and the delivery date.

Scope a custom review